首页> 外文期刊>European journal of ophthalmology >Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion.
【24h】

Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion.

机译:玻璃体内曲安奈德用于治疗视网膜中央静脉阻塞。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To evaluate the effect of intravitreal triamcinolone acetonide on visual acuity and intraocular pressure in patients with central retinal vein occlusion. METHODS: This prospective comparative non-randomized clinical interventional study included 32 patients (33 eyes) with central retinal vein occlusion. The study group (12 patients; 13 eyes) received an intravitreal injection of about 20 mg of triamcinolone acetonide. The control group (20 patients) did not receive any treatment. Mean follow-up was 10.1+/-8.6 months in the study group and 6.0+/-5.2 months in the control group. RESULTS: In the study group, mean visual acuity increased significantly (p=0.018) from 0.11+/-0.11 preoperatively to a best visual acuity during follow-up of 0.18+/-0.15. An improvement in visual acuity by at least 2 Snellen lines and 3 Snellen lines, respectively, was found for 8 (62%) eyes and 5 (38) eyes. Visual acuity measurements determined 1 month (p=0.038) and 3 months (p=0.046) after the injection were significantly higher than the baseline values. Increase in visual acuity was higher in the non-ischemic subgroup than in the ischemic subgroup. In the control group, baseline visual acuity and best visual acuity during the followup did not vary significantly (p=0.33). Visual acuity decreased significantly (p=0.007) towards the end of the follow-up. Comparing study group and control group, gain in visual acuity was significantly (p=0.01) higher in the study group. In the study group, intraocular pressure increased significantly (p=0.018) from 14.4+/-3.9 mmHg to a mean maximal value of 21.6+/-9.2 mmHg (range, 10-44 mmHg), and re-decreased (p=0.012) towards the end of follow-up to 15.3+/-5.1 mmHg (range, 10-21 mmHg). CONCLUSIONS: Intravitreal triamcinolone acetonide temporarily increases visual acuity in central retinal vein occlusion. It is accompanied by an increase in intraocular pressure.
机译:目的:评价玻璃体腔注射曲安奈德对视网膜中央静脉阻塞患者视力和眼压的影响。方法:这项前瞻性比较非随机临床干预研究包括32例(33眼)视网膜中央静脉阻塞。研究组(12名患者; 13眼)接受了约20 mg曲安奈德的玻璃体内注射。对照组(20名患者)未接受任何治疗。研究组的平均随访时间为10.1 +/- 8.6个月,对照组为6.0 +/- 5.2个月。结果:在研究组中,平均视力从术前的0.11 +/- 0.11显着提高(p = 0.018)至随访期间的最佳视力0.18 +/- 0.15。发现8只眼(62%)和5只眼(38)的视力分别提高了至少2条Snellen线和3条Snellen线。注射后1个月(p = 0.038)和3个月(p = 0.046)测得的视敏度明显高于基线值。非缺血性亚组的视敏度增加高于缺血性亚组。在对照组中,随访期间的基线视力和最佳视力没有显着差异(p = 0.33)。在随访末期,视力显着下降(p = 0.007)。与研究组和对照组相比,研究组的视力提高显着(p = 0.01)。在研究组中,眼内压从14.4 +/- 3.9 mmHg显着增加(p = 0.018)至21.6 +/- 9.2 mmHg的平均最大值(范围10-44 mmHg),然后降低(p = 0.012) ),直至随访结束时达到15.3 +/- 5.1 mmHg(范围10-21 mmHg)。结论:玻璃体内曲安奈德可暂时增加视网膜中央静脉阻塞的视力。伴随有眼内压升高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号